BMSSC
PTCT icon

B. Metzler seel. Sohn & Co’s PTC Therapeutics PTCT Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,712
Closed -$890K – 742
2025
Q4 		$890K Sell
11,712
-3,670
-24% -$267K 0.01% 560
2025
Q3 		$944K Buy
+15,382
New +$801K 0.01% 551

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

B. Metzler seel. Sohn & Co's PTCT Position: Q1 2026 in Review

B. Metzler seel. Sohn & Co sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 11,712 shares — an estimated $890K sold.

B. Metzler seel. Sohn & Co first reported a position in PTCT in Q3 2025 and held it in 2 quarters. The position peaked at $944K in Q3 2025. 351 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • B. Metzler seel. Sohn & Co reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 11,712 PTC Therapeutics shares in Q1 2026, an estimated $890K.
  • B. Metzler seel. Sohn & Co first reported a position in PTC Therapeutics in Q3 2025 and held it in 2 quarters.
  • B. Metzler seel. Sohn & Co's PTC Therapeutics position peaked at $944K in Q3 2025.
  • 351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q1 2026, filed 8 May 2026.